An independent panel of three epidemiologists have concluded that exposure to the manufacturing substance known as C8 or PFOA is linked to two types of cancer in Mid Ohio Valley residents.
The C8 Science Panel released their new findings on Monday morning. It‘s the latest development in the class action lawsuit brought by local residents against DuPont over the presence of the manufacturing chemical PFOA, or perfluorooctanoic acid, in their drinking water. As a result of the findings, a medical panel has been established to determine what type of medical monitoring is appropriate for class members.
What began as the C8 Health Project has become the largest study ever undertaken to determine the link between PFOA exposure and cancer. An analysis of 21 types of cancer yielded two probable link findings.
Read the full story in The Anchor:
http://www.theanchornews.net/index.php?option=com_content&view=article&id=1096:web-extra-c8-science-panel-links-c8-to-testicular-kidney-cancer&catid=2:community-news&Itemid=15
Monday, April 16, 2012
Thursday, April 12, 2012
New Findings Expected Monday
The C8 Science Panel will release their next set of probable link findings on Monday morning in Vienna, West Virginia. Health concerns to be addressed include diabetes and cancer.
The panel of three epidemiologists are wrapping up their work, which will determine the outcome of the Mid Ohio Valley class action lawsuit brought by residents against DuPont over the presence of the manufacturing substance, PFOA, in their public water supplies.
The term “probable link” is court terminology, not scientific jargon. Specifically, the C8 Science Panel was convened for the purpose of determining whether, given the available scientific evidence, there is "more likely than not" a connection between PFOA exposure and human disease in class members.
In December, the panel released their conclusion that there was an association between C8 exposure and pregnancy induced hypertension. The panel is scheduled to release all of their findings by the end of July.
The panel of three epidemiologists are wrapping up their work, which will determine the outcome of the Mid Ohio Valley class action lawsuit brought by residents against DuPont over the presence of the manufacturing substance, PFOA, in their public water supplies.
The term “probable link” is court terminology, not scientific jargon. Specifically, the C8 Science Panel was convened for the purpose of determining whether, given the available scientific evidence, there is "more likely than not" a connection between PFOA exposure and human disease in class members.
In December, the panel released their conclusion that there was an association between C8 exposure and pregnancy induced hypertension. The panel is scheduled to release all of their findings by the end of July.
C8 Medical Panel Appointed
DuPont and attorneys for local residents who settled a class action lawsuit against DuPont in 2005 over releases of C8 or PFOA from DuPont’s Washington Works plant announced today that they have jointly selected a three member panel of independent, well-qualified and respected medical doctors – the “C8 Medical Panel” – to determine the nature and extent of whatever medical monitoring may be appropriate under the terms of the settlement.
Read the full story in The Anchor:
http://www.theanchornews.net/index.php?option=com_content&view=article&id=1094:web-extra-c8-medical-panel-selected&catid=2:community-news&Itemid=15
Read the full story in The Anchor:
http://www.theanchornews.net/index.php?option=com_content&view=article&id=1094:web-extra-c8-medical-panel-selected&catid=2:community-news&Itemid=15
Tuesday, December 6, 2011
C8 Science Panel Finds Link to Human Disease
There is a link between C8 exposure and human disease, according to the C8 Science Panel who released their first set of probable link findings this week. The panel determined that there is a link between exposure to PFOA, or perfluorooctanoic acid, and pregnancy-induced hypertension.
This is significant because the development triggers the next phase of settlement in the class action lawsuit brought by Mid Ohio Valley residents against DuPont over the presence of the manmade chemical in several public water supplies. DuPont has used C8 for more than fifty years at Washington Works near Parkersburg, W.Va., in the manufacture of Teflon and many other consumer applications.
The panel’s determination was based on data from the C8 Health Project and four related studies which identified more than 3,000 cases of pregnancy-induced hypertension in exposed populations. Similarly, a link was detected between C8 exposure and preeclampsia.
The panel did not find a probable link between C8 exposure and pregnancy loss, low birth weight, or birth defects.
Dr. David Savitz explained the panel’s findings, calling pregnancy-induced hypertension a “serious complication of pregnancy” and one that is known to increase the risk of preterm birth.
While the condition typically resolves with the birth of the baby, Savitz said women who develop high blood pressure during pregnancy are at an increased risk of having it again with subsequent pregnancies. He said pregnancy-induced hypertension is also a “predictor” of problems later in life.
Even so, Savitz said the number one cause of pregnancy-induced hypertension is obesity, which is something that can be more directly addressed by women of childbearing age. He also encouraged expectant mothers to fully participate in prenatal care - and to follow the advice of their doctors.
The term “probable link” is court terminology, not scientific jargon. Specifically, the C8 Science Panel was appointed for the purpose of determining whether, given the available scientific evidence, there is more likely than not a connection between PFOA exposure and human disease in class members.
As a result of the panel’s findings, a medical panel will be established to determine whether medical monitoring is called for under the terms of the settlement. At the conclusion of the suit, if a “probable link” has been found, the settlement agreement provides for $235 million to be paid out by DuPont for medical monitoring.
The C8 Science Panel is expected to release two more sets of findings before concluding their work in July 2012.
DuPont officials say they do not believe that PFOA causes pregnancy-induced hypertension, but they will move forward with their obligations under the settlement agreement.
“DuPont has committed to no longer make, buy or use PFOA by 2015, or sooner if possible,” company officials said in a statement. “We have made significant progress toward this commitment, including commercializing next-generation offerings that are made without using PFOA, and that cannot break down to PFOA in the environment.”
The company has requested a permit change in order to replace the controversial manufacturing substance. Documents obtained from the West Virginia Department of Environmental Protection indicate the new substance intended for use in fluoropolymer production is called by the trade name C3. In the permit application, DuPont calls the new technology a “sustainable solution that includes a new processing aid with a favorable toxicological profile and rapid bioelimination”.
Little else is known about the substance. DuPont’s permit, if it is successful, would allow C3 to be discharged into the Ohio River. WVDEP is accepting public comments on the matter until December 26.
This is significant because the development triggers the next phase of settlement in the class action lawsuit brought by Mid Ohio Valley residents against DuPont over the presence of the manmade chemical in several public water supplies. DuPont has used C8 for more than fifty years at Washington Works near Parkersburg, W.Va., in the manufacture of Teflon and many other consumer applications.
The panel’s determination was based on data from the C8 Health Project and four related studies which identified more than 3,000 cases of pregnancy-induced hypertension in exposed populations. Similarly, a link was detected between C8 exposure and preeclampsia.
The panel did not find a probable link between C8 exposure and pregnancy loss, low birth weight, or birth defects.
Dr. David Savitz explained the panel’s findings, calling pregnancy-induced hypertension a “serious complication of pregnancy” and one that is known to increase the risk of preterm birth.
While the condition typically resolves with the birth of the baby, Savitz said women who develop high blood pressure during pregnancy are at an increased risk of having it again with subsequent pregnancies. He said pregnancy-induced hypertension is also a “predictor” of problems later in life.
Even so, Savitz said the number one cause of pregnancy-induced hypertension is obesity, which is something that can be more directly addressed by women of childbearing age. He also encouraged expectant mothers to fully participate in prenatal care - and to follow the advice of their doctors.
The term “probable link” is court terminology, not scientific jargon. Specifically, the C8 Science Panel was appointed for the purpose of determining whether, given the available scientific evidence, there is more likely than not a connection between PFOA exposure and human disease in class members.
As a result of the panel’s findings, a medical panel will be established to determine whether medical monitoring is called for under the terms of the settlement. At the conclusion of the suit, if a “probable link” has been found, the settlement agreement provides for $235 million to be paid out by DuPont for medical monitoring.
The C8 Science Panel is expected to release two more sets of findings before concluding their work in July 2012.
DuPont officials say they do not believe that PFOA causes pregnancy-induced hypertension, but they will move forward with their obligations under the settlement agreement.
“DuPont has committed to no longer make, buy or use PFOA by 2015, or sooner if possible,” company officials said in a statement. “We have made significant progress toward this commitment, including commercializing next-generation offerings that are made without using PFOA, and that cannot break down to PFOA in the environment.”
The company has requested a permit change in order to replace the controversial manufacturing substance. Documents obtained from the West Virginia Department of Environmental Protection indicate the new substance intended for use in fluoropolymer production is called by the trade name C3. In the permit application, DuPont calls the new technology a “sustainable solution that includes a new processing aid with a favorable toxicological profile and rapid bioelimination”.
Little else is known about the substance. DuPont’s permit, if it is successful, would allow C3 to be discharged into the Ohio River. WVDEP is accepting public comments on the matter until December 26.
Monday, September 5, 2011
Researchers Collaborate on C8 Findings
Conclusions about data gathered in the C8 Health Project are coming from two primary sources but the relationship between the C8 Science Panel and West Virginia University researchers is described as being more collaborative than competitive in nature.
In recent weeks, media attention has been drawn to study reports on C8 exposure released by two groups of researchers who are working from the same body of data. Dr. Kyle Steenland, one of three members of the C8 Science Panel, says both parties have access to the same database from the C8 Health Project collected in 2005 and 2006. In order to cover a lot of territory and not duplicate each other’s work, the two groups of researchers have made some agreements to work together.
Read the full story at: http://www.theanchornews.net/index.php?option=com_content&view=article&id=729:researchers-collaborate-on-c8-findings&catid=1:localpolitical&Itemid=15
In recent weeks, media attention has been drawn to study reports on C8 exposure released by two groups of researchers who are working from the same body of data. Dr. Kyle Steenland, one of three members of the C8 Science Panel, says both parties have access to the same database from the C8 Health Project collected in 2005 and 2006. In order to cover a lot of territory and not duplicate each other’s work, the two groups of researchers have made some agreements to work together.
Read the full story at: http://www.theanchornews.net/index.php?option=com_content&view=article&id=729:researchers-collaborate-on-c8-findings&catid=1:localpolitical&Itemid=15
WVU Researchers: C8 Linked to Osteoarthritis
In addition to the release of new information from the C8 Science Panel, researchers at West Virginia University have drawn some of their own conclusions about exposure based on data from the C8 Health Project.
Researchers looked at the incidence of osteoarthritis reported by more adult participants of the health project. Osteoarthritis is the most common degenerative joint disease, characterized by pain and stiffness that worsen with physical activity.
Read the full story at: http://www.theanchornews.net/index.php?option=com_content&view=article&id=708:wvu-researchers-c8-linked-to-osteoarthritis&catid=1:localpolitical&Itemid=15
Researchers looked at the incidence of osteoarthritis reported by more adult participants of the health project. Osteoarthritis is the most common degenerative joint disease, characterized by pain and stiffness that worsen with physical activity.
Read the full story at: http://www.theanchornews.net/index.php?option=com_content&view=article&id=708:wvu-researchers-c8-linked-to-osteoarthritis&catid=1:localpolitical&Itemid=15
Panel: C8 Exposure Linked to Liver Function, Preeclampsia
New findings on C8 exposure have been released as a court appointed Science Panel works toward completion of their investigation into the chemical’s potential for human health effects. The results provide answers to some looming questions about the manufacturing substance known as PFOA or perfluorooctanoic acid, which has been used at DuPont Washington Works to produce Teflon since the 1950s.
Read the full story at: http://www.theanchornews.net/index.php?option=com_content&view=article&id=709:panel-c8-exposure-linked-to-liver-function-preeclampsia&catid=1:localpolitical&Itemid=15
Subscribe to:
Posts (Atom)